INHIBITION OF MIR26A MICRORNA RESTORES SENSITIVITY TO TEMOZOLOMIDE by Stewart, Angela G.
Northern Michigan University
NMU Commons
All NMU Master's Theses Student Works
2012
INHIBITION OF MIR26A MICRORNA
RESTORES SENSITIVITY TO
TEMOZOLOMIDE
Angela G. Stewart
Northern Michigan University
Follow this and additional works at: https://commons.nmu.edu/theses
This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been accepted for inclusion in All NMU
Master's Theses by an authorized administrator of NMU Commons. For more information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.
Recommended Citation
Stewart, Angela G., "INHIBITION OF MIR26A MICRORNA RESTORES SENSITIVITY TO TEMOZOLOMIDE" (2012). All
NMU Master's Theses. 513.
https://commons.nmu.edu/theses/513
 
 
INHIBITION OF MIR26A 
MICRORNA RESTORES 
SENSITIVITY TO 
TEMOZOLOMIDE 
by 
Angela G Stewart  
A thesis submitted in partial fulfillment of 
the requirements for the degree of 
Masters of Science  
Northern Michigan University 
2012 
 
 
 
 
 
 
 
SIGNATURE APPROVAL PAGE 
Title of Thesis:  
Inhibition of MiR26a MicroRNA Restores Sensitivity to Temozolomide 
This thesis by Angela G. Stewart is recommended for approval by the student’s 
Thesis Committee and  Department Head in the Department of Biology and by 
the Assistant Provost of Graduate Education and Research.  
 
Committee Chair: Robert Winn Ph.D.  Date 
 
First Reader: Donna Becker, Ph.D. Date 
 
Second Reader: Richard Rovin, M.D.  Date 
 
Department Head: John Rebers, Ph.D  Date 
 
 
Dr. Brian Cherry Date 
Assistant Provost of Graduate Education and Research 
i 
 
ABSTRACT 
Inhibition of miR26a microRNA restores sensitivity to temozolomide 
by Angela Grace Stewart 
MicroRNAs have been associated with tumorgenesis of Glioblastoma Multiforme 
(GBM). A microRNA (miRNA) is a small RNA (22-25 nucleotides) that can prevent 
the translation of messenger RNA (mRNA) into protein by binding the mRNA         
(Huse et al. 2008, Zamore and Haley 2005). The miRNA/mRNA complex is then 
degraded. PTEN is a tumor suppressor protein which regulates the AKT/PIP3 
pathway, which is active in many cellular regulatory pathways. The microRNA miR-26a 
is known to bind PTEN mRNA. The loss of PTEN promotes ideal conditions for the 
unregulated growth of tumor cells and Huse et al. (2008) demonstrated that miR-26a is 
frequently amplified in human glioma. Jiang and colleagues (2007) reported that the 
lack of PTEN influences the cells ability to resist chemotherapy treatment, specifically 
temozolomide (TMZ). TMZ is the current chemotherapy standard of care for GBM 
patients. This study investigated a possible link between miR-26a inhibition and TMZ 
sensitivity. LN229 glioma cell line (wild-type PTEN and miR-26a positive) was treated 
with a miR26a oligo inhibitor, and subsequent TMZ treatment. Cellular proliferation 
was assayed. We demonstrated that treatment of LN229 glioma cells with the 
combination of microRNA inhibitor and TMZ resulted in a marked decrease in cell 
proliferation and viability. 
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INTRODUCTION 
Glioblastoma multiforme (GBM) is one of the most common and aggressive 
types of brain tumors (Huse et al. 2008). The World Health Organization (WHO) 
classifies GBM as a grade IV tumor due to its poor prognosis and median 
survival of 14 months after diagnosis. GBMs are heterogeneous; a single tumor 
may have a variety of cell types with distinct alterations to specific signal 
transduction pathways.   GBM requires aggressive treatment including surgery, 
chemotherapy and radiation, however there has been little advancement in GBM 
treatments since the introduction of temozolomide as a treatment option.  
Inactivation of PTEN has been shown to be involved in the formation of 
heritable and sporadic cancers (Planchon 2007). It has been demonstrated that 
the AKT signaling pathway can be continuously activated in GBMs, and in some 
cases this activation is due, in part, to the loss of Phosphatase and Tensin 
Homolog (PTEN) expression. PTEN contains both a protein phosphatase and a 
tensin-like region involved in cell adhesion and is a negative regulator of the AKT 
pathway. AKT is a serine/threonine protein kinase with several important roles 
in multiple cellular processes including; cell proliferation, cell survival, 
transcription and cell migration (Wang 2012). Phosphatidylinositol 3, 4, 5 tri-
phosphate (PIP3), is a signaling molecule that activates AKT, setting in motion a 
cascade of signaling pathways. PTEN negatively regulates the AKT signaling 
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pathway by dephosphorylating PIP3 to phosphatidylinositol 4, 5 bi-phosphate 
(PIP2) and PIP2 cannot activate AKT thus preventing unregulated cell growth. 
With the loss of PTEN, PIP3 can accumulate within the cell creating a consistent 
stream of activation for AKT.  
Additionally a recent review paper by Parsa et al. (2007) showed a connection 
between the loss of PTEN and an increase in B7-H1 cell surface receptors on 
GBM cells. B7 is traditionally a receptor on antigen presenting cells, that when 
paired with the CD28 receptor of T cells causes a stimulatory signal to illicit an 
immune response. B7-H1 (B7 homolog) which is up regulated with the loss of 
PTEN assists the tumor cells in evading the immune system. The signal produced 
when T cells interact with B7-H1 is inhibitory and prevents a response.  PTEN 
deficient cells were thus rendered less susceptible to cytotoxic T lymphocyte-
mediated targeting (Waziri et al. 2010).  Tumor specific T cells were found to lyse 
human glioma targets expressing wild-type PTEN more effectively than those 
expressing mutant PTEN; this data identifies an unrecognized mechanism linking 
loss of the tumor suppressor PTEN with immunoresistance (Parsa et al. 2007). 
Treatment of patients with drugs that selectively target cancer cells with loss of 
PTEN could improve response to T cell mediated immunotherapy by decreasing 
local immunoresistance (Parsa et al. 2007).  The results of Parsa et al. (2007) 
could impact immunotherapy trials by defining the loss of PTEN function as 
important molecular screening criteria.  
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 Recent studies have shown that PTEN can be epigenetically silenced. 
Epigenetics is a way of altering gene expression that does not involve changes in 
the nucleotide sequence of DNA or RNA. Epigenetic regulation is manifested as 
methyl groups added to DNA/RNA following replication or miRNA binding to 
mRNA preventing translation. Another epigenetic regulator of PTEN is miR-26a 
microRNA. 
 MicroRNAs (miRNAs) are small (~22 nucleotides), post-transcriptional 
regulators that bind to complementary sequences in the three prime untranslated 
regions (3’ UTR) of target messenger RNA transcripts (mRNAs), usually 
resulting in gene silencing (Huse et al. 2008). MiRNAs are small noncoding RNA 
molecules that regulate protein expression by targeting the mRNA of protein 
coding genes for either cleavage or repression of translation (Chan et al. 2005). 
The miRNA works to sequester the mRNA by binding to it and preventing 
translation. Most miRNA genes are found in intergenic regions (between gene 
clusters) making it an endogenous molecule. The miRNA genes contain their 
own promoter and regulatory units. MiR-26a in particular acts on the mRNA of 
PTEN, acting as a miRNA associated with cancer or oncomiR that negatively 
regulates PTEN protein. Huse et al. (2008) demonstrated that miR-26a is 
frequently amplified in human glioma, and miR-26a-mediated PTEN repression 
in a murine glioma model enhances de novo tumor formation. The biogenesis of 
miRNA requires several posttranscriptional steps to yield the functional mature 
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miRNA (Esquela-Kerscher and Slack 2006). MiRNAs are created by the 
microprocessor complex of Drosha and DGCR8 (Esquela-Kerscher and Slack 
2006). Drosha is in the RNAse-III family and is activated when bound to the 
nuclear protein DGCR8 (which is also known as pasha).This complex cleaves the 
correct 70 nucleotides from the miRNA gene creating the primary miRNA (pri-
miRNA). The pri-miRNA is then cleaved into a double stranded stem and loop 
conformation with a 2 nucleotide overhang, resulting in what is known as the 
preliminary miRNA (pre-miRNA). The pre-miRNA is exported out of the 
nucleus by exportin-5, which recognizes the 2 nucleotide overhang, and Ran-
GTP. Ran-GTP or Ras associated nuclear protein transports molecules in/out of 
the nucleus. This action of transport is dependent on the hydrolysis of guanine 
triphosphate (GTP) to guanine diphosphate (GDP). Once in the cytoplasm the 
pre-miRNA complex binds to Dicer. Dicer is an endoribonuclease that cleaves 
the pre-miRNA duplex. The now single strands of miRNA are considered 
mature. When the mature miRNA is combined with the RNA-induced silencing 
complex (RISC) the miRISC is formed (Esquela-Kerscher 2006). The miRISC is 
the machinery that binds to mRNA transcripts allowing the miRNA to interact 
with its target mRNA. Degradation of the target mRNA only occurs if there is 
perfect complementary binding. Some miRNA-mRNA binding complexes are 
not perfectly complementary; the result is steric hindrance of the translational 
machinery preventing mRNA translation into a functional protein (Figure 1). 
5 
 
PTEN is often referred to as a haploinsufficient gene (Salmena et al. 2008). 
Following the loss of one allele the remaining allele is not sufficient to produce a 
functional protein. Epigenetic alterations such as miR-26a binding to the mRNA 
of PTEN, prevents the production of a functional protein without loss of the 
PTEN gene.  It has also been demonstrated in a murine model that over 
expression of the miRNA can functionally substitute for the loss of 
heterozygosity at the PTEN locus, leading to the haploinsufficient state of the 
gene (Huse et al. 2008). Even with an intact PTEN locus, the over expression of 
miR-26a creates the same haploinsufficient state as if the locus were deleted or 
mutated. The roles of miRNAs in lineage determination and proliferation as well 
as the location of several miRNA genes at sites of translocation breakpoints or 
deletions has led to the speculation that miRNAs could be important factors in 
the development or maintenance of the neoplastic state (Chan et al. 2005). As of 
yet, no microRNA has been definitively shown to either enhance or suppress the 
process of glioma formation in vivo. However, it has been demonstrated that miR-
26a reduces PTEN levels by directly targeting the PTEN mRNA transcript, by 
binding to one of three known binding sites (Huse et al. 2008). With the loss of a 
tumor suppressor gene, such as PTEN, the cell might be more likely to undergo 
transformation. Additionally if PTEN has a role in TMZ functionality its loss 
would increase chemotherapy resistance.  
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Jiang and colleagues (2007) reported that decreased PTEN expression plays a role 
in the cell’s ability to resist chemotherapy treatment, specifically temozolomide. 
They reported that inducing PTEN expression down regulated AKT activity and 
enhanced cell sensitivity to TMZ. The exact mechanism for TMZ resistance due 
to PTEN loss is unknown at this time however it is speculated that the level of 
phosphorylated AKT might play a role. Temozolomide is the current standard of 
care for GBM chemotherapy and acts as an alkylating agent that adds a methyl 
group to the O6 or N7 position on guanine residues in the cell’s DNA.  This 
alteration to the DNA activates the cells mis-match repair system (MMR) 
(Chamberlain and Mrugala 2008). Continued mis-match by the cell’s MMR 
mechanism creates accumulations of double stranded breaks. Ultimately cell 
proliferation is halted by either apoptosis or termination of cell division, due to 
the accumulation of DNA damage. An intact mis-match repair mechanism is 
required for TMZ induced cytotoxicity (Chamberlain and Mrugala 2008).  
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PROJECT OBJECTIVES 
 
The GBM cell line LN229 (ATCC#CRL-2611) is reported to contain the wild-
type PTEN gene, but also expresses the miRNA miR-26a (Huse et al. 2008, 
Furnari et al. 1997). The LN229 cell line was established from a female 
glioblastoma patient in 1979 (ATCC). The presence of miR-26a has an effect on 
PTEN’s tumor suppressor ability by preventing translation of the genetic 
information into a protein (Huse et al. 2008). If the presence of PTEN in the cell 
is thought to increase the potency of its tumor suppression ability, the 
knockdown of miR-26a should increase the amount of PTEN protein and 
increase the LN229 cells sensitivity to chemotherapy agents such as TMZ. This 
research examined the hypothesis that silencing of miR-26a will allow PTEN to 
be translated into protein increasing the cells sensitivity to TMZ, resulting in a 
decrease in the cells viability. The following steps were used to support this 
hypothesis: LN229 glioma cells were confirmed to contain miR-26a using RT-
PCR. The miRNA was silenced with the transfection of an anti-miR-26a 
oligonucleotide producing a decrease in cell viability. Relative levels of PTEN 
protein were examined using a western blot, before and after transfection with 
anti-miR26a. Temozolomide was then combined with the anti-miR-26a treatment 
to verify further decrease in cell viability.  
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Chapter 1 
PTEN: a tumor suppressor 
Structure and Function of PTEN 
Phosphatase and Tensin homolog (PTEN) is a lipid phosphatase tumor 
suppressor protein. A ubiquitous inhibitor of the AKT pathway by 
dephosphorylation of PIP3, PTEN assists in regulation of the cell cycle to 
prevent unregulated growth (Leslie and Downes 2004). A member of the protein 
tyrosine phosphatase family, PTEN removes phosphates from phosphorylated 
tyrosine residues on proteins. Removal of the phosphate in the 3 position on the 
inositol ring of tyrosine prevents activation of the AKT pathway by termination 
of PIP3 signaling (Wang et al. 2012). The AKT pathway is responsible for cellular 
survival mechanisms: glucose metabolism, cellular proliferation, prevention of 
apoptosis, and cell migration (Wang et al. 2012). PIP3 binds AKT activating the 
protein; once activated AKT moves to the cytoplasm and nucleus allowing for 
stimulation of several downstream targets involved in cellular functions (Wang et 
al. 2012).  The level of PIP3 is very low in resting cells that contain wild type 
PTEN. Cells that lack PTEN have elevated levels of PIP3, even in the resting 
state. (Sulis and Parsons 2003).  Functional PTEN maintains the cell cycle within 
normal operating parameters; however a loss of functional PTEN can allow 
unregulated cellular growth with the potential to become cancerous. 
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Mechanisms for loss of PTEN in Glioblastoma 
The PTEN gene, which encodes for the PTEN protein, is located on 
chromosome 10 and in some glioblastoma cases the locus for the PTEN gene is 
mutated or deleted. Even partial loss of the PTEN gene prevents protein 
production due to a haploinsufficient state (Leslie and Downes 2004 Salmena et 
al. 2008). Haploinsufficiency is when one locus is not suitable to produce 
adequate amounts of functional protein. The loss of functional protein can result 
from mechanisms other than gene deletion. Leslie and Downes (2004) noted that 
54% of glioblastomas have a loss of expression of PTEN, meaning there could 
be an intrinsic mechanism preventing protein production. Epigenetic alteration of 
the PTEN mRNA transcript would alter the amount of protein expressed in the 
cell. Epigenetics manifest as methyl groups added to DNA/RNA or miRNA 
binding post-transcriptionally. MicroRNAs are post-transcriptional regulators that 
prevent translation of mRNAs and ultimately protein production. PTEN has two 
well-known microRNAs found in GBMs that bind and prevent its protein 
production; miR-21 and miR26a (Leslie and Foti 2011). The latter miRNA is 
known to have 3 binding sites on the PTEN mRNA transcript, making it a more 
attractive target for therapy (Huse et al. 2008).  
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Materials and Methods 
Western Blot 
LN229 cells were plated at a density of 5x104 cells/well in a 24-well plate. The 
cells were then harvested 24 hours later to create a whole cell lysate. Sample lysis 
buffer was placed in boiling water to warm. The sample lysis buffer was 
composed of 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 1% 
SDS with a pH of 7.3. One hundred to 150 microliters of sample lysis buffer was 
administered to each of the 24 wells to lyse the cells. The lysate was pipetted to 
mix, collected and pooled, resulting in 4 mL total volume. The LN229 lysate was 
determined to contain 1.1 µg/µL of protein using a BCA protein assay (Bio-Rad).  
The lysate sample was combined with Laemmli sample buffer and pipetted into a 
Bio-Rad SDS-Page pre cast gel in 15 µL and 50 µL volumes. The gel was run in 
1x tris/Glycine/SDS running buffer at a constant voltage (39 v) for 55 minutes. 
The gel was then placed on a nitrocellulose sheet in a Bio-Rad transfer cassette. 
The transfer cassette was placed in western transfer solution (Tris 48 mM, 
Glycine 39 mM, SDS 0.04%, 200 mL methanol and 800 mL dH20) in the BIO-
RAD Power Pack machine at constant amperage 0.10 A, 39 v and 4 w for 10 
hours. After the transfer, the nitrocellulose paper was placed in a 3% nonfat milk 
blocking buffer for 30 min. The primary antibody, mouse monoclonal anti-
PTEN (Calbiochem), was applied in a 1:200 dilution and incubated for 11 hours. 
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The secondary antibody, goat anti-mouse labeled with horseradish peroxidase 
(Thermo scientific), was applied in a 1:1000 dilution, for 1 hour. Between the 
primary and secondary antibody applications the membrane was washed 3 times 
for 15 min each in TBST (Table 1). Following final antibody incubation the 
membrane was washed 3 more times in TBST prior to visualization. 
Visualization 
Protein was visualized using SuperSignal ELISA Pico Chemiluminescent 
Substrate (Bio-Rad). A 1:1 ratio (undiluted) of the substrate was applied to the 
nitrocellulose paper. The proteins were imaged immediately using Kodak 1D 
image system (Figure 2).  
Results/Discussion 
PTEN was confirmed to be present within the LN229 cell line as indicated by 
well-defined bands in the western blot (Figure 2). This result was expected as the 
LN229 cell line was previously reported to be wild-type for the PTEN protein 
(Furnari et al. 1997). PTEN expression was expected due to the intact wild-type 
gene. However if miR-26a is present the amount of protein should be decreased 
but not necessarily completely eliminated. A decrease in PTEN protein may be 
sufficient to alter the tumor suppressor role of PTEN and to alter the cells 
response to the chemotherapy agent TMZ. 
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Chapter 2 
Temozolomide: Current Standard of Care 
Action of Temozolomide 
Temozolomide (chemical structure: 3, 4-dihydro-3-methyl-4-oxoimidaso [5, 1-d]-
1, 2, 3, 5-tetrazine-8-caboxamide) is the current standard of care for 
chemotherapy treatment of GBM. The drug has been used since August of 1999 
in the United States. TMZ is efficiently absorbed after oral administration, and 
readily crosses the blood-brain barrier (Chamberlain and Mrugala 2008).  The 
therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA. 
TMZ adds a methyl group to either the O6 or N7 position on guanine residues. 
The presence of the methyl group on the O6 position of the guanine residues 
causes mis-matching during DNA replication, the guanine is matched with a 
thymidine as opposed to a cytosine (Chamberlain and Mrugala 2008). The mis-
match triggers activation of the cell’s mis-match repair system (MMR).  The 
MMR system removes the incorrect base pair match and the replication is 
resumed. However, the same mis-match occurs again, due to the ongoing 
presence of the methyl group. This mis-match and the futile repair keep 
occurring until numerous double-stranded DNA breaks accumulate in the cell. It 
is the accumulation of these double-stranded DNA breaks that leads the cell to 
apoptosis.   
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Loss of PTEN and chemotherapy resistance 
In breast cancer, reduction of PTEN by antisense oligonucleotides conferred 
trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast 
cancers had significantly poorer responses to trastuzumab-based therapy than 
those with normal PTEN (Nagata et al. 2004).  It has been demonstrated that 
loss of PTEN decreases cells sensitivity to chemotherapy treatments in several 
types of cancer and chemotherapies. In GBM decreased PTEN levels reduced 
cell sensitivity to TMZ and induction of PTEN expression was found to enhance 
cell sensitivity to TMZ (Jiang et al. 2007).  PTEN can sensitize glioma cells to 
chemotherapy and also induce apoptosis (Wang et al. 2002). When PTEN is 
present it can sensitize cells to TMZ, allowing TMZ to have a greater affect in 
decreasing cell viability compared to cells where PTEN is not present. Jiang et al. 
(2007) also found that by inducing PTEN, in PTEN-deficient cells, TMZ 
sensitivity was restored through a decrease in AKT pathway activity. The 
induction of wild-type PTEN in U251-wtPTEN cells led to a statistically 
significant increase in sensitivity to a range of temozolomide doses from 10 to 50 
µmol/L (Jiang et al. 2007). The exact mechanism for the increase of sensitivity to 
TMZ when functional PTEN is present has yet to be elucidated. It has been 
suggested that a deficiency in MMR coupled with the haploinsufficiency of 
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PTEN can account for resistance to TMZ and tumor progression. It has been 
shown that MMR deficiency can accelerate tumorgenesis in PTEN +/- mice 
(Wang et al. 2002).  Another cellular mechanism that confers resistance to TMZ 
is the presence of O6-methylguanine-DNA methyltransferase (MGMT). As 
stated, TMZ is an alkylating agent that acts on the O6 or N7 positions on guanine 
residues in DNA. The DNA changes created by TMZ are a major carcinogenic 
lesion. The cell has mechanisms to repair such lesions; one mechanism is the 
enzyme MGMT. MGMT is a suicide repair protein that removes the cytotoxic 
O6 guanine produced by the alkylator-based chemotherapy, thereby inducing 
resistance (Chamberlain and Mrugala 2008). The repair protein is not regenerated 
once the alkyl group is removed. It has been reported that LN229 cells do not 
express MGMT (Davis 2008). The lack of MGMT expression in LN229 cells 
rules out MGMT as a mechanism for resistance. 
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Chapter 3 
MicroRNA: Small RNAs with big impact 
Biogenesis, Structure and Function 
 MicroRNAs are endogenous small RNAs that bind the 3’ UTR of target mRNA 
transcripts. The miRNA genes possess all the necessary machinery to produce a 
functional mature miRNA. The biogenesis of miRNA begins with the RNAse-III 
enzyme Drosha and its cofactor DGCR8 (Esquela-Kerscher and Slack 2006). 
DGCR8 is also known as pasha; a protein localized to the nucleus. Pasha binds to 
Drosha forming the microprocessor complex. Pasha is thought to stabilize the 
pri-miRNA for binding by Drosha (Esquela-Kerscher and Slack 2006). The 
Drosha and DGCR8 complex recognizes the pri-miRNA sequence and cleave 
the strand into a 70 nucleotide dsRNA with a 2 nucleotide overhang (Zamore 
and Haley 2005). Once cleaved the pri-miRNA has a stem-loop conformation 
with an overhang, this is now known as the pre-miRNA (Turner et al. 2010). The 
pre-miRNA overhang is recognized by exportin-5 and Ran-GTPase which 
exports the pre-miRNA, from the nucleus. Exportin-5 mediates transport of 
cargo from the nucleus into the cytoplasm by interacting with Ran. Ran-GTPase 
transports molecules in/out of the nucleus during interphase of mitosis. This 
action of transport is GTP dependent, meaning the energy from the hydrolysis of 
GTP to GDP is necessary. Once in the cytoplasm the pre-miRNA is further 
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digested by Dicer (Turner et al. 2010). Dicer is an endoribonuclease in the RNase 
III family that cleaves the pre-miRNA into short double-stranded RNA 
fragments. Cleavage by Dicer creates a mature miRNA (Turner et al. 2010). Dicer 
then catalyzes the first step in the miRNA mediated interference of protein 
expression. Formation of the RNA-induced silencing complex (RISC) allows the 
mature miRNA to bind the target mRNA. RISC is also known as a microRNA 
ribonucleoprotein complex (miRNP) and RISC with incorporated miRNA is 
sometimes referred to as “miRISC” (Zamore and Haley 2005).  The miRNP 
RISC can either perfectly match the target mRNA transcript resulting in 
degradation of the whole complex or bind and prevent translation due to steric 
hindrance if not completely complementary (Esquela-Kerscher and Slack 2006; 
Figure 1).  
Materials and Methods 
Cell Culture 
The glioblastoma cell line LN229 (ATCC#CRL-2611) was used. LN229s were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM), 5% FBS. The cell 
line was maintained without antibiotics, at 37°C in a humidified atmosphere 
containing 5% CO2.  
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Determination of miR-26a presence in LN229 cell line was accomplished by 
SYBR Green miScript Reverse Transcription PCR. 
Reverse Transcription 
RNA Isolation/Purification 
RNeasy Mini Kit (Qiagen) was used to isolate and purify total RNA, including 
miRNA from the LN229 glioma cells following the manufacturer’s protocol. 
Briefly, cells were grown in a culture flask as a monolayer until 90% confluent. 
The cells were treated with trypsin-EDTA and pelleted prior to lysis. Cells were 
disrupted by adding 600 µL of Buffer RLT to the pellet and then vortexed. The 
lysate was pipetted directly into a QIAshredder spin column placed in a 2 mL 
collection tube, centrifuged for 2 minutes at >8000 x g. One volume (600 µL) of 
70% ethanol was added to the homogenized lysate, and mixed by pipetting. Up to 
700 µL of the sample was transferred to an RNeasy spin column in a 2 mL 
collection tube. The lid was closed securely and centrifuged for 15 seconds (s) at 
>8000 x g. The flow through was discarded. Buffer RW1 (700 µL) was added to 
the RNeasy spin column. The sample was centrifuged again for 15 s at >8000 x g. 
Buffer RPE (500 µL) was added to the RNeasy spin column and centrifuged for 
15 s at > 8000 x g, the flow through was again discarded. An additional 2 minute 
centrifugation was performed with RPE buffer (500 µL) to wash the spin column 
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membrane (> 8000 x g). The RNeasy spin column was placed in a new 1.5 mL 
collection tube and centrifuged for 1 minute at > 8,000 x g to elute miRNA.  
Reverse transcription (RT) 
A master mix was created using the guidelines provided in the miScript PCR 
System Handbook (Qiagen) (Table 2). The master mix was placed on ice until the 
RNA reaction was prepared. The RNA template was prepared as follows: For 
each 20 μL RT reaction, master mix was combined with total RNA in the ratio of 
1 μL master mix: up to 1 μg total RNA (10pg to 1μg per reaction). MiScript RT 
buffer (4 μL) was combined with a pre-designed PTEN primer from Qiagen 
(UUCAAGUAAUCCAGGAUAGGCU) and RT master mix; incubated for 60 
minutes at 37⁰C then incubated for 5 minutes at 95⁰C to inactivate miScript 
Reverse Transcriptase mix.  Tubes were stored at -20⁰C if not proceeding directly 
to PCR amplification of cDNA. 
Real Time-PCR Amplification 
A reaction volume of 20 μL was pipetted into a 48-well plate using the following: 
Volume/reaction: 10 μL QuantiTect SYBR Green PCR Master Mix (Qiagen), 1 
μL Product from RT reaction (cDNA), 2μL 10x miScript Universal 
Primer(Qiagen), 2 μL 10x HS_miR-26a-1_1 miScript Primer Assay(Qiagen), 5 μL 
of Nuclease-free water (Table 3). Twenty microliters of each sample was placed 
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into the wells of a 48-well plate. The plate was centrifuged briefly to mix the 
reagents thoroughly. The tubes were held at 95°C for 15 minutes, and then the 
following thermal cycling conditions used were: 15 seconds at 94°C to denature, 
30 seconds at 55°C to anneal 30 seconds at 70°C for extension (Figure 3). There 
were 40 cycles run.  
Results 
The results for the amplification of miR-26a are shown in Figure 4. Each sample 
well tested showed positive amplification for miR-26a compared to the negative 
control. This data confirms the presence of the target miRNA within the LN229 
glioma cell line.  
Discussion 
The LN229 cell line was found to contain the miRNA in question, miR-26a. This 
result was expected as the LN229 glioma cell line had previously been reported to 
contain the microRNA miR26a (Huse et al. 2008). Given these results it could be 
predicted that knockdown of miR26a should have an effect on the cellular level 
of PTEN protein and the viability of the LN229 glioma cell line.  
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Chapter 4 
MicroRNA Inhibition 
Background 
Studies using LN229 GBM cell lines indicate PTEN is “silenced” in a post-
translational mechanism by miR-26a miRNA (Nicoloso and Calin 2008). 
Silencing of miR-26a was accomplished via transfection of a miScript miRNA 
inhibitor, Anti-has-miR-26a-1 oligonucleotide (Qiagen). Anti-has-miR-26a-1 is a 
modified antisense single–stranded oligonucleotide (Qiagen). It is designed to be 
complementary to the miR-26a miRNA and specifically inhibits its expression by 
binding to miR-26a. Binding of Anti-has-miR-26a-1 oligonucleotide to miR-26a 
prevents the miRNA from binding to the PTEN transcript. Transfection was 
completed using the Neon transfection system (Invitrogen) using electroporation. 
Electroporation is a method used to increase the electrical conductivity and 
permeability of the cell plasma membrane, by an externally applied electrical field. 
This method is used to introduce new or foreign substances into a cell, such as 
anti-miR26a oligonucleotide.  The viability of the LN229 cells was determined by 
quantitation of the amount of ATP. The luminescence signal generated correlates 
with the amount of ATP present, which is directly proportional to the number of 
live cells in culture. The smaller the luminescent signal the fewer the number of 
live cells present. Western blot was employed to detect increased presence of 
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PTEN protein. Knocking down/silencing miR-26a should allow PTEN mRNA 
to be translated and potentially increase protein expression.  
 
Materials and Methods 
Transfection 
Twenty wells of a 96-well plate were used to create and incubate the transfected 
cell suspensions (Table 4). Four different miR26a inhibitor concentrations were 
used to treat each cell suspension. Untreated cells were electroporated with buffer 
only. Inhibitor treated cells were electroporated with the following concentrations 
of inhibitor: 50 µM (1.5 µL distilled water, 0.50 µL anti-has-miR-26a-1); 75 µM 
(1.25 µL distilled water, 0.75 µL anti-has-miR-26a-1); 100 µM (1.0 µL distilled 
water, 1.0 µL anti-has-miR-26a-1); and 200 µM (2.0 µL anti-has-miR-26a-1). The 
original stock concentration of the anti-has-miR-26a-1 was 100 nmol. LN229 
cells were diluted to 5x103 cells per well in 56 µL of resuspension buffer R 
(Invitrogen). Anti-has-miR-26a-1 miScript miRNA inhibitor (Qiagen) treatment 
was accomplished by electroporation using the Neon Transfection system 
(Invitrogen). Ten microliters of cell suspension including anti-has-miR26a-1-
miScript miRNA was placed in the Neon pipette station with 3 mL of electrolytic 
buffer E (Invitrogen). The LN229 cells were treated with the following 
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parameters; Pulse voltage 1050 v, and 40 ms width.  This should provide a 
transfection efficiency of 73% and a cell viability of 80% as previously 
determined by Invitrogen (Table 5).   The cell suspension post-pulse was placed 
into complete media and incubated at 37°C for a 24 hour period. 
CellTiter-Glo Luminescent Assay 
After 24 hours of incubation the plate was equilibrated to room temperature for 
30 minutes. CellTiter-Glo reagents were added to each well in an amount equal to 
the cell culture media (100 µL was used). Contents were mixed for 2 minutes, the 
plate was then incubated at room temperature for 10 minutes to stabilize 
luminescent signal (Figure 5). Luminescence was recorded at an integration time 
of 1 second per well on the Turner Biosystems Modulus microplate luminometer. 
Luminescence was measured in relative light units, which correlate with the 
number of active cells within the sample.  
Statistics 
Statistical analysis of data was performed using IBM SPSS Statistics 19 and 
Microsoft Excel. A one way ANOVA with Tukey post hoc test was performed 
on the luminescence data to determine if there was a significant difference 
between the luminescence amounts in the five treatment groups: untreated, 50 
µM, 75 µM, 100 µM and 200 µM. 
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Western Blot 
LN229 cells were plated at a density of 5 x 104 cells/well in a 24-well plate.  Ten 
microliters of LN229 cells were transfected with anti-has-miR26a-1 at a 
concentration of 100 µM with resuspension buffer R (Invitrogen) using the Neon 
Transfection system (Invitrogen) as previously described. The cells were then 
harvested 24 hours later by direct application of sample lysis buffer to each well.  
The lysed cells were used to create a whole cell lysate. Lysis buffer contained 20 
mM HEPES and 1% SDS at a pH of 7.3. Sample lysis buffer was placed in 
boiling water to warm. One hundred to 150 μL of sample lysis buffer was 
administered to each of the 24 wells to lyse the cells. The lysate was pipetted to 
mix, collected and pooled in a 15 mL tube, resulting in 4mL total volume.  The 
LN229 lysate was determined to contain 0.457 ng/µL of protein (Figure 6).  The 
lysate sample was combined with Laemmli sample buffer and pipetted into a Bio-
Rad SDS-Page pre cast gel in 10 µL and 50 µL amounts. The gel was run in 1x 
tris/Glycine/SDS running buffer at constant voltage (39 v) for 55 minutes. The 
gel was then placed on a nitrocellulose sheet in a transfer cassette (BIO-RAD). 
The transfer cassette was placed in western transfer solution (Tris 48 mM, 
Glycine 39 mM, SDS 0.04%, 200 mL methanol and 800 mL dH20) at constant 
amperage 0.10 A, 39 v and 4 w for 10 hours. After the transfer the nitrocellulose 
paper was placed in a 3% nonfat milk blocking buffer for 30 min. The primary 
antibody, mouse monoclonal anti-PTEN was applied in a 1:200 dilution and 
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incubated for 11 hours. The secondary antibody, goat anti-mouse labeled with 
horseradish peroxidase (Thermo scientific), was applied in a 1:1000 dilution for 1 
hour. Between the primary and secondary antibody applications the membrane 
was washed 3 times for 15 min each in TBST (Table 1). Following final antibody 
incubation the membrane was washed 3 more time in TBST prior to 
visualization.  
Visualization 
Protein was visualized using SuperSignal ELISA Pico Chemiluminescent 
Substrate. A 1:1 ratio (undiluted) of the substrate was applied to the nitrocellulose 
paper. The proteins were imaged using Kodak 1D (Figure 7).  
Results 
A range of anti-miR26a concentrations were tested; 50, 75, 100 and 200 μM to 
determine which concentration had the greatest effect. Each treatment amount of 
anti-miR26a had a significant effect (P=0.0004) compared to untreated cells 
(Figure 8). The anti-miR26a treatment was consistent in decreasing the LN229 
cell line viability through all concentrations, over a 24 hour period. The 
electroporation alone did not have a significant effect on cell viability; all 
untreated cells were electroporated in subsequent experiments.  The western blot 
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showed a greater amount of PTEN protein in the anti-miR26a treated LN229 
cells, determined by visual inspection (Figure 7).  
Discussion 
It is clear the inhibition of miR-26a reduced the LN229 cell viability and PTEN 
protein levels. Tumor suppressor genes are subject to numerous regulatory 
mechanisms including epigenetic effects and posttranslational modifications that 
ultimately govern protein levels, activity, binding partners and function (Salmena 
et al. 2008).  It was demonstrated in studying three human glioblastoma samples 
that miR-26a directly targets PTEN and enhances the AKT pathway; transfecting 
miR-26a into a murine model showed that over expression enhances 
gliomagenesis (Turner et al. 2010). In this study it was demonstrated that 
inhibition of miR26a in a cell line that is expressing it, was successful in 
decreasing the cells viability. The decrease in cell viability could be due to an 
increased amount of PTEN protein. The western blot showed an increase in the 
amount of PTEN protein within the LN229 cells treated with anti-miR26a 
(Figure 7). The quantification of the increase in PTEN protein amount was based 
upon visual inspection. It can be inferred that the increase of PTEN protein 
resulted in the decrease in cell viability, possibly due to a reduction in active AKT, 
but further research would need to be completed to confirm this.  
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Chapter 5 
Combination Temozolomide and miR-26a inhibitor Treatment 
Background 
If the demonstrated inhibition of miR-26a was successful in restoring functional 
PTEN protein it is likely to make the LN229 cells more sensitive to 
chemotherapy treatment with TMZ. A combination treatment with the anti-miR-
26a inhibitor and 400 uM (the EC50 dose of TMZ) (Moroz et al. 2011) was tested. 
Materials and Methods 
Transfection 
Thirty wells of a 96 well plate were used to incubate anti-has-miR-26a-1 and 
TMZ treated LN229 cells at a density of 5x103 cells/well in 56 µL of 
resuspension buffer R (Invitrogen).  Cell suspension (100 µL per well) was placed 
in a 96 well plate as described in Table 6.  Anti-has-miR-26a-1 concentrations 
used were as follows: 75 µM (1.25 µL distilled water, 0.75 µL anti-has-miR-26a-1); 
100 µM (1.0 µL distilled water, 1.0 µL anti-has-miR26a-1); and 200 µM (2.0 µL 
anti-has-miR26a-1. The 50 µM treatment was not used in combination treatment 
due to inconsistent results. Transfection of anti-has-miR26a was accomplished by 
electroporation using the Neon Transfection System (Invitrogen). Ten microliters 
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of cell suspension (cells and resuspension buffer R), including anti-has-miR26a-1, 
was placed in the Neon pipette station in 3 mL of electrolytic buffer E 
(Invitrogen). The following treatment parameters were applied; Pulse voltage 
1050 v, and 40 ms width. This should provide a transfection efficiency of 73% 
and a cell viability of 80% as previously determined by Invitrogen (Table 5).   The 
cell suspension post-pulse was placed into complete media containing EC50 
dosage of TMZ (400uM) (Moroz et al. 2011). The cells were incubated at 37°C 
for a 24 hour period. 
CellTiter-Glo Luminescent Assay 
After 24 hours of incubation the plate was equilibrated to room temperature for 
30 minutes. CellTiter-Glo reagents were added to each well in an amount equal to 
the cell culture media of each well (100 µL was used). Contents were mixed for 2 
minutes, the plate was then incubated at room temperature for 10 minutes to 
stabilize luminescent signal. Luminescence was recorded at an integration time of 
1 second per well on the Turner Biosystems Modulus microplate luminometer. 
This test should show if indeed the presence of functional PTEN within the cell 
is beneficial for increasing a chemotherapy agent’s effect and decreasing the 
LN229 cells viability.  Three different trials were completed; each was conducted 
as a separate experiment to ensure results were consistent.  
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Statistics 
Statistical analysis of data was performed using IBM SPSS Statistics 19 and 
Microsoft Excel. A one way ANOVA with Tukey post hoc test was performed 
on the luminescence data to determine if there was a significant difference 
between the luminescence amounts in the three treatment groups: untreated, 
inhibitor only treated, TMZ only and combination (TMZ and inhibitor) 
treatment.  
Results 
Compared to anti-has-miR26a-1 treatment only the combination treatment of 
anti-has-miR26a-1 and TMZ  significantly decreased cell viability over a 24 hour 
period in trial 1 (Figure 9). Trial 2 (Figure 10) shows the combination of Anti-
has-miR26a miRNA and TMZ treatment had a greater effect on decreasing cell 
viability than the inhibitor only.  
Discussion 
Statistical analysis of data was performed to determine significant between 
miR26a inhibitor treated LN229 cells and untreated LN229 cells. A one-way 
ANOVA with Tukey post-hoc test confirmed a significant difference (P=0.0001) 
between the treatment groups (inhibitor, TMZ, and combination).  The decrease 
in cell viability is thought to be due to an increase in functional PTEN protein, 
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this was supported by the western blot results (Figure 7). The combination of 
TMZ and miR-26a inhibitor had a greater effect on LN229 cell viability then 
either inhibitor or TMZ only in trial 3 (Figure 11). The inhibitor only treatment 
reduced cell viability and appeared to cause an increase in PTEN protein. Even 
with the PTEN protein increase the inhibitor only treatment was not as effective 
at reducing cell viability as the TMZ only or combination treatments in trials 2 
and 3. The inhibitor only might have been less effective because of residual 
activated AKT present in the cell. The results of the combination treatment 
showed further reduction in cell viability which appeared to be greater than either 
the anti-miR26a or TMZ treatments alone. These results indicate that miR-26a is 
a viable target to increase the efficacy of TMZ treatment. The electroporation did 
not have a significant effect on the cell growth. 
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SYNOPSIS AND CONCLUSIONS  
This study showed the inhibition of miR-26a when combined with TMZ 
treatment results in an increased TMZ response and a decrease in cell viability. 
This suggests that the presence of the anti-miR26a oligo binds miR-26a and 
inhibits its ability to decrease the translation of PTEN mRNA into protein. 
Down regulation of miR-26a could be confirmed by real time PCR, but was not 
in this study. The up regulation of PTEN protein was visually confirmed by the 
western blot of the anti-has-miR-26a miRNA treated cells. The LN229 cells were 
successfully transfected using the Neon transfection system (Invitrogen) through 
electroporation. The electroporation did not have a significant effect on the 
LN229 cells viability. Other means of PTEN detection could be used to verify up 
regulation. PCR for the mRNA PTEN transcript could be used to compare pre 
and post transfection levels. Immunocytochemistry could be used to stain the 
cells directly for PTEN protein presence. MiR-26a has a complex role in cancer. 
It has been demonstrated in hepatocellular carcinoma miR26a has reduced 
expression compared to the high levels of normal expression in diverse tissue 
(Kota et al. 2009). A balance is needed for miRNAs to help regulate normal 
cellular proliferation. The literature has support for both sides of the tumor 
suppressor/oncogenic argument, indicating the need for a clearer picture of 
miRNAs involvement in tumorgenesis. Clearly inhibition of miR26a has an effect 
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on the viability of LN229 cells. This is a beneficial finding because inhibition of 
miR-26a allows the current standard of GBM care, TMZ, to work more 
effectively.  All results indicate miR-26a miRNA is a plausible target in GBM 
therapy.  
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FUTURE DIRECTIONS 
Other studies that could be performed to further this research would be to 
compare these results with similar tests performed on PTEN mutated cells, such 
as the U87 GBM cell line. Comparing wild-type PTEN cells with mutated PTEN 
cells would give a greater indication that miR26a is in fact inhibiting PTEN 
protein production. Additionally looking at downstream effects of anti-miR26a 
application would be helpful in clarify the miRNAs function. Targets such at 
AKT activity after treatment with anti-miR26a might help create a clearer picture 
of the effect miR26a has on the cell cycle. Exiqon has been developing a protocol 
to sample amounts of miRNA within serum samples from patients. This protocol 
has the potential to be used as a prognostic factor for the severity of one’s tumor; 
currently the protocol only involves colo-rectal cancer.  This is a potential 
stepping stone for a non-invasive test to determine a patient’s tumor severity, 
possible even how a tumor would react to chemotherapy treatment with TMZ. 
For example if a patient had a blood sample taken and miR26a was found in a 
substantial amount it could be inferred that the tumor might be less sensitive to 
TMZ than if there was no miR26a present in the sample. The fact that miRNA 
overexpression in cancer has a pathogenic effect provides the rationale for using 
miRNAs as potential therapeutic targets in cancer.  A robust increase in miR-21 
expression was found in six commonly used model cell lines derived from human 
33 
 
glioblastoma, this represents only initial studies that should be followed by large 
trials in patients with brain cancers to support the biomarker roles for miRNAs    
( Nicoloso & Calin 2008). 
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APPENDIX A 
 
Figures and Tables 
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Figure 1.Biogenesis of microRNA. Begins in the nucleus with Drosha and 
Pasha. Once in the cytoplasm Dicer cleaves the double stranded miRNA 
complex to create a mature miRNA. Mature miRNA can then assemble miRISC. 
If imperfect complementarity translation is repressed, perfect complementarity is 
cleaved and degraded (Esquela-Kerscher and Slack 2006).  
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Figure 2. Western Blot for PTEN. The clear bands imaged confirm PTEN 
protein within LN229 lysate.  The lysate amount from left to right is 15 µL, 50 
µL, 15 µL and 50 µL.  
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Figure 3. RT-PCR Cycling conditions for RT- PCR using StepOne Real-Time 
PCR System, 40 cycles were completed.  
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Figure 4.  Amplification of miR-26a using RT-PCR.  Primer RNA for miR-
26a (UUCAAGUAAUCCAAGGAUAGGCU) was combined with RT buffer 
and RT master mix to create cDNA for miR-26a. The cDNA was combined with 
SYBR Green PCR master mix and HS_miR-26a1_1 primer to produce the above 
amplification plot. The change in Rn shows an increase in miR-26a as cycles 
continue; this confirms the presence of miR-26a in the LN229 cells.  
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Figure 5. Cell-Titer Glo Reaction. Cell-Titer Glo measures cell viability by 
presence of ATP, and is directly proportional to the amount of active cells 
present in the suspension. The reaction shows how luminescence is created to 
provide quantitation of ATP present.  
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Figure 6. BCA Protein Concentration. Standard graph of 
protein concentrations used to determine amount of protein 
in LN 229 lysate sample (0.457 µg/ µL) 
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Figure 7. Western Blot of PTEN:  post transfection. Visually there was an 
increase in the amount of PTEN in the treated cells compared to the untreated 
cells.  
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Figure 8. Cell viability after treatment with anti-miR-26a oligo. There is a 
significant decrease in cell viability in the LN229 cells treated with all anti-miR-
26a oligo concentrations compared to the untreated LN229 cells at all inhibitor 
concentrations (P=0.0004). There was no significant difference between the 
concentration amounts. 
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Figure 9. Silencing of miR-26a 24 hours post transfection trial 1. Untreated 
cells had the greatest luminecense indicating more viabile cells were present in 
that treatment. Inhibitor only had  less luminecense then TMZ only.  The 
combination treatment had the least amount of luminecense indicating the least 
amount of active cells. The bars with the same letters do not differ, the bars with 
differing letters are significantly different (P=0.00001).  
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Figure 10. LN229 inhibition of miR-26a combined with TMZ trial 2. It is 
clear the combination of miR26a inhibitor with TMZ had a greater effect on 
LN229 cell viability compared to inhibitor alone, the different letters indicate 
significant difference between treatments (P=0.0001).  A one way ANOVA was 
performed with Tukey post-hoc (P=0.0001), indicating there is a significant 
difference between the treatment groups (untreated, inhibitor only, and 
combination. The bars with the same letters do not differ.  
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Figure 11. Cell viability of LN229 cell line after miR-26a inhibition plus 
TMZ trial 3. Once again the combination treatment (miR26a inhibitor and 
TMZ) had a significant effect on LN229 cell viability after 24 hours of application 
compared to the TMZ and anti-miR26a only treatments (P<0.001). Differing 
letters indicate the significant difference between treatments (untreated, inhibitor 
only, TMZ only, and inhibitor and TMZ).  
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Table 1.  TBST Solution. Western transfer solution components. 
 
 
 
 
 
 
 
Table 2. Reaction components for reverse transcription. Reverse 
transcription was performed on total extracted RNA from LN229 cells. The 
resulting cDNA was used in PCR for amplification of miR-26a, confirming 
presence in the cell line. 
 
 
 
 
 
Component Concentration
/ Amount 
Tris 48 mM (5.8g) 
Glycine 39 mM  (2.9g) 
SDS 0.04% (0.37g) 
Methanol 200 mL 
Distilled H2O 800 mL 
Component Volume 
1 reaction (µ L) 
miScript RT Buffer, 
5x 
4  
RNase-free Water 14  
miScript Reverse 
Transcriptase mix 
1 
Template RNA 1 µg 
TOTAL 20 
 1 
 
 
 
 
Table 3. Reaction components for PCR Assay. PCR was performed in the 
StepOne Real-Time PCR cycler. Amplification of miR26a confirmed its presence 
in the LN229 cell line.  
 
 
 
 
 
 
 
 
Component Volume  
1 reaction (µL) 
2x QuantiTect SYBR Green 
PCR Master Mix  
10 
10x miScript Universal 
Primer 
2 
10x miScript Hs_miR-26a-
1_1 Primer Assay 
2 
RNase-free Water 5 
Template cDNA 1 
TOTAL 20 
 1 
 
Table 4.  Well Plate Template. Schmatic of 96-well plate set up for cell 
incubation after  Neon Transfection of miR-26a inhibitor. MiR-26a inhibitor 
wells contained 10 uL of cell suspension and 90 uL of complete media. Untreated 
cells were electroporated and placed into complete media; they contained no 
inhibitor.   
 
 
 
 
 
 
 
 Anti-
miR-26a 
Anti-
miR-26a  
LN229 
Cells 
LN229 
Cells 
  
       
A 0 µ M 0 um Untreated Untreated   
B 50 µ M 50 µ M Untreated Untreated   
C 75 µ M 75 µ M Untreated Untreated   
D 100 µ M 100 µ M Untreated Untreated   
E 200 µ M 200 µ M Untreated Untreated   
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Table 5. Electroporation parameters. Parameters for electroporation of glioma 
cell lines as previously determined by Invitrogen, for successful transfection.  
 
 
 
 
 
 
 
 
 
 
 
Electroporation parameters 
Pulse 
voltage 
(v) 
Pulse 
width 
(ms) 
Pulse 
number 
Cell 
density 
(cells/ml) 
Transfection 
efficiency 
Viability Tip type 
1,050 40 1 5 x 106 73%  80% 10 μl 
       
 1 
 
 
Table 6. Combination treatment plate setup. The following 96 well plate 
schematic illustrates the setup for transfection with miR-26a inhibitor plus TMZ 
treatment. The plate was read using the Cell-Titer Glo Cell Viability assay 24 
hours after treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miR26a 
Inhibitor 
miR26a 
Inhibitor 
  miR26a 
Inhibitor 
&TMZ 
miR26a 
Inhibitor 
&TMZ 
       
              
A 0 µ M 0 um Untreated Untreated 0 µ M 0 µ M  TMZ 
only 
     
B 75 µ M 75 µ M Untreated Untreated 75 µ M 75 µ M  TMZ 
only 
     
C 100 µ M 100 µ M Untreated Untreated 100 µ M 100 µ M  TMZ 
only 
     
D 200 µ M 200 µ M Untreated Untreated  200 µ M  TMZ 
only 
     
              
